unknown by Yoseph Shaaltiel et al.
 
Plant Biotechnology Journal
 
 (2007) 
 
5
 
, pp. 579–590 doi: 10.1111/j.1467-7652.2007.00263.x
© 2007 Protalix Biotherapeutics
Journal compilation © 2007 Blackwell Publishing Ltd
 
579
 
Blackwell Publishing Ltd Oxford, UK PBI Plant Biotechnology Journal 1467-7644 © 2007 Blackwell Publishing Ltd XXX Original Articles
 
Glucocerebrosidase from plant cells for treating Gaucher’s disease
 
Yoseph Shaaltiel 
 
et al.
 
Production of glucocerebrosidase with terminal mannose 
glycans for enzyme replacement therapy of Gaucher’s 
disease using a plant cell system
 
Yoseph Shaaltiel
 
1
 
, Daniel Bartfeld
 
1
 
, Sharon Hashmueli
 
1
 
, Gideon Baum
 
1
 
, Einat Brill-Almon
 
1
 
, Gad Galili
 
2
 
, 
Orly Dym
 
3,4
 
, Swetlana A. Boldin-Adamsky
 
5
 
, Israel Silman
 
4,6
 
, Joel L. Sussman
 
3,4
 
, Anthony H. Futerman
 
5
 
 
and David Aviezer
 
1,
 
*
 
1
 
Protalix Biotherapeutics, 2 Snunit Street, Science Park, Carmiel 20100, Israel
 
2
 
Department of Plant Biology, Weizmann Institute of Science, Rehovot 76100, Israel
 
3
 
Department of Structural Biology, Weizmann Institute of Science, Rehovot 76100, Israel
 
4
 
Israel Structural Proteomics Center, Weizmann Institute of Science, Rehovot 76100, Israel
 
5
 
Department of Biological Chemistry, Weizmann Institute of Science, Rehovot 76100, Israel
 
6
 
Department of Neurobiology, Weizmann Institute of Science, Rehovot 76100, Israel
 
Summary
 
Gaucher’s disease, a lysosomal storage disorder caused by mutations in the gene encoding 
glucocerebrosidase (GCD), is currently treated by enzyme replacement therapy using 
recombinant GCD (Cerezyme
 
®
 
) expressed in Chinese hamster ovary (CHO) cells. As complex 
glycans in mammalian cells do not terminate in mannose residues, which are essential for 
the biological uptake of GCD via macrophage mannose receptors in human patients with 
Gaucher’s disease, an 
 
in vitro
 
 glycan modification is required in order to expose the 
mannose residues on the glycans of Cerezyme
 
®
 
. In this report, the production of a 
recombinant human GCD in a carrot cell suspension culture is described. The recombinant 
plant-derived GCD (prGCD) is targeted to the storage vacuoles, using a plant-specific 
C-terminal sorting signal. Notably, the recombinant human GCD expressed in the carrot 
cells naturally contains terminal mannose residues on its complex glycans, apparently as 
a result of the activity of a special vacuolar enzyme that modifies complex glycans. Hence, 
the plant-produced recombinant human GCD does not require exposure of mannose 
residues 
 
in vitro
 
, which is a requirement for the production of Cerezyme
 
®
 
. prGCD also 
displays a level of biological activity similar to that of Cerezyme
 
®
 
 produced in CHO cells, 
as well as a highly homologous high-resolution three-dimensional structure, determined by 
X-ray crystallography. A single-dose toxicity study with prGCD in mice demonstrated the 
absence of treatment-related adverse reactions or clinical findings, indicating the potential 
safety of prGCD. prGCD is currently undergoing clinical studies, and may offer a new and 
 
alternative therapeutic option for Gaucher’s disease.
 
Introduction
 
Gaucher’s disease is the most prevalent lysosomal storage
disorder, and occurs with a particularly high frequency in the
Ashkenazi Jewish population (Lee, 1982; Grabowski, 1993;
Beutler and Grabowski, 2001). It is caused by mutations in the
gene encoding glucocerebrosidase (GCD), a lysosomal enzyme
that catalyses the hydrolysis of glucosylceramide (glucocere-
broside, GlcCer), leading to GlcCer accumulation, primarily in
the lysosomes of macrophages. The characteristic storage cells,
known as Gaucher cells, are found in the liver, spleen and bone
marrow. Associated clinical symptoms include hepatosplenom-
egaly, anaemia, thrombocytopenia and skeletal deterioration
(Grabowski and Hopkin, 2003; Jmoudiak and Futerman, 2005).
GCD consists of 497 amino acids, and contains five putative
 
N
 
-glycosylation sites, four of which are normally occupied
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(Berg-Fussman 
 
et al
 
., 1993; Brumshtein 
 
et al
 
., 2006). Glyco-
sylation is essential for the production of an active protein,
with both high-mannose (Man) and complex oligosaccharide
chains found in GCD (Berg-Fussman 
 
et al
 
., 1993). As Gau-
cher’s disease is a monogenic disease, it can be treated by
replacement of the defective gene product, GCD; hence, the
rationale underlying ‘enzyme replacement therapy’ (ERT)
(Barton 
 
et al
 
., 1991; Pastores 
 
et al
 
., 1993; Grabowski 
 
et al
 
.,
1995; Weinreb 
 
et al
 
., 2002; Grabowski and Hopkin, 2003;
Beutler, 2004). An effective clinical outcome is achieved in
patients with Gaucher’s disease treated with recombinant
GCD expressed in mammalian Chinese hamster ovary (CHO)
cells: Cerezyme
 
®
 
 (Grabowski 
 
et al
 
., 1995; Weinreb 
 
et al
 
., 2002;
Jmoudiak and Futerman, 2005).
In order for GCD to be effective in ERT, terminal Man
residues must be present on the glycan chains to permit
binding to macrophage Man receptors, and subsequent
internalization (Sato and Beutler, 1993; Bijsterbosch 
 
et al
 
.,
1996). Cerezyme
 
®
 
  production involves sequential 
 
in vitro
 
deglycosylation, using 
 
α
 
-neuraminidase, 
 
β
 
-galactosidase and
 
β
 
-
 
N
 
-acetylglucosaminidase, to expose terminal Man residues,
a procedure which dramatically improves targeting and
internalization (Furbish 
 
et al
 
., 1981; Doebber 
 
et al
 
., 1982;
Bijsterbosch 
 
et al
 
., 1996; Friedman 
 
et al
 
., 1999).
The objective of this study was to provide a novel and alter-
native plant-based method for the industrial-scale production
of GCD for use in ERT. The use of plant cell cultures for the
production of human biopharmaceutical proteins has been
under evaluation in recent years (Hellwig 
 
et al
 
., 2004). Plant
cell cultures offer several advantages over both field-grown
transgenic plants and mammalian cell cultures. They are
cost-effective, do not involve the use of mammalian-derived
components in the manufacturing process, have high
batch-to-batch reproducibility, allow precise control over the
growth process, and enable compliance with current Good
Manufacturing Procedures (Hellwig 
 
et al
 
., 2004).
In this report, the expression of a recombinant human GCD
in a plant cell expression system, based on transgenic carrot
cells grown in suspension culture, is described, which is cap-
able of the production of glycoproteins. It is shown that GCD
expression in carrot cells (prGCD), together with its targeting
to the storage vacuole, generates a protein with terminal
Man structures 
 
in vivo
 
, thus precluding the need for post-
production enzymatic modification 
 
in vitro
 
 (Lerouge 
 
et al
 
.,
1998; Friedman 
 
et al
 
., 1999; Gomord and Faye, 2004). It is
demonstrated that prGCD is structurally highly homologous
to Cerezyme
 
®
 
, and displays comparable enzymatic activity
and uptake into macrophages. Furthermore, a single-dose
safety study in ICR (CD-1
 
®
 
) mice, with doses up to 18 mg/kg
administered by intravenous infusion, demonstrates that there
are no adverse reactions, clinical or pathological findings, in-
dicating the potential safety of the plant cell-expressed GCD.
 
Results
 
GCD expression in carrot cells
 
A number of modifications in the native human GCD sequence
were made in order to permit its efficient expression and
activity. The GCD signal peptide was replaced by that of the
 
Arabidopsis thaliana
 
 basic endochitinase gene to facilitate
co-translational translocation into the endoplasmic reticulum
(ER) (Samac 
 
et al
 
., 1990), and the storage vacuole targeting
signal from tobacco chitinase A, encoding the sequence
DLLVDTM (Neuhaus 
 
et al
 
., 1991), was fused to the C-terminus
to facilitate GCD targeting via the ER to this organelle
(Figure 1). Plant storage vacuoles are generally considered to
contain relatively low levels of proteases (Neuhaus and Rogers,
1988), and some studies also indicate that plant vacuoles
may possess activities that expose terminal Man on complex
glycans (Lerouge 
 
et al
 
., 1998). A number of antibiotic-resistant
transgenic calli were obtained. Many of them expressed a
protein band with the expected size of a glycosylated GCD,
which cross-reacted in immunoblots with antihuman GCD
antibodies. Such a protein band was not detected in control
non-transformed calli, verifying its identity as prGCD (data
not shown).
 
Purification and characterization of prGCD
 
prGCD was solubilized using Triton X-100 in the presence
of an antioxidant, and purified to homogeneity by cation
exchange and hydrophobic chromatography (Figure  2b,c).
Amino acid sequencing demonstrated that the prGCD
sequence corresponds to that of human GCD (Swiss Prot
P04062, protein ID AAA35873) (Figure 2a), and includes two
additional amino acids (EF) at the N-terminus (designated -2
Figure 1 Glucocerebrosidase (GCD) gene used in the plant expression 
system. The expression cassette consists of the cauliflower mosaic virus 
(CaMV) 35S promoter, the tobacco mosaic virus (TMV) omega 
translational enhancer element, a signal peptide, the human GCD 
sequence, a vacuolar targeting signal and the octopine synthase 
terminator sequence from Agrobacterium tumefaciens. 
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and -1 accordingly), derived from the linker used for the
fusion of the signal peptide, and an additional seven amino
acids at the C-terminus (designated 497–503), derived from
the vacuolar targeting signal.
 
Glycan structures
 
Glycosylation was analysed (Glycobiology Center of the
National Institute for Biotechnology, Ben Gurion University,
Beer Sheba, Israel) to determine the glycan structure and gly-
can quantitative ratio using sequential digestion with various
exoglycosidases (see ‘Experimental procedures’). It was found
that the 
 
N
 
-linked glycans have a main core of two 
 
N
 
-
acetylglucosamine (GlcNAc) residues and a 
 
β
 
1–4-linked Man,
attached to two additional Man residues in 
 
α
 
1–3 and 
 
α
 
1–6
linkages. The additional residues found are shown in Figure 3a,
which presents all structures and their relative amounts based
on high-performance liquid chromatography (HPLC), enzyme
array digests and delayed extraction-matrix-assisted laser
desorption ionization-time of flight-mass spectrometry (DE-
MALDI-TOF-MS). Figure  3b shows the glycan structure of
Cerezyme
 
®
 
 before and after 
 
in vitro
 
 enzymatic processing.
Notably, the analysis of the glycan structures of prGCD
revealed that more than 90% of the glycans were Man rich,
bearing terminal Man residues (Figure 3a), whereas, in the
case of Cerezyme
 
®
 
, Man residues were exposed only after a
complex 
 
in vitro
 
 procedure (Figure 3b). The dominant glycan
in prGCD was the core structure found in most glycoproteins
purified from pea, rice, maize and other edible plants
(Lerouge 
 
et al
 
., 1998; Bardor 
 
et al
 
., 2003; Gomord and Faye,
2004). This structure contains a core 
 
α
 
-(1,2)-xylose residue as
well as a core 
 
α
 
-(1,3)-fucose (Figure 3a). DE-MALDI-TOF-MS
data contained no signals consistent with typical 
 
O
 
-linked
glycans. Further analysis of the glycan profiles for prGCD
obtained from different production batches was performed
in order to assess the batch-to-batch reproducibility of
prGCD produced in the carrot cell system. As shown in
Figure 4, the population of glycans on prGCD was highly
reproducible between batches.
 
Enzymatic activity
 
The activity of prGCD was compared with that of Cerezyme
 
®
 
using a fluorescent GlcCer analogue (Meivar-Levy 
 
et al
 
.,
1994). Similar specific activities were obtained (Figure  5),
with 
 
V
 
max
 
 values of 0.47 
 
±
 
 0.08 
 
µ
 
mol 
 
N
 
-[6-[(7-nitrobenzo-
2-oxa-1,3-diazol-4-yl)amino]hexanoyl]-glucosylsphingosine
(C6-NBD-GlcCer) formed/min/mg protein for prGCD and
Figure 2 Characterization of recombinant 
plant-derived glucocerebrosidase (prGCD). 
(a) Amino acid sequence of prGCD. (b) prGCD 
(lanes 1 and 2; 5 and 10 µg of protein, 
respectively) and Cerezyme
® (lanes 3 and 4; 
5 and 10 µg of protein, respectively) were 
detected by sodium dodecylsulphate-
polyacrylamide gel electrophoresis (SDS-PAGE) 
and Coomassie blue staining. (c) Western 
blotting using an anti-GCD antibody: prGCD, 
lanes 1 and 2 (50 and 100 ng of protein, 
respectively); Cerezyme
®, lanes 3 and 4 (50 and 
100 ng of protein, respectively). 
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0.43 
 
±
 
 0.06 
 
µ
 
mol for Cerezyme
 
®
 
, and similar 
 
K
 
m
 
  values
(20.7 
 
±
 
 0.7 
 
µ
 
M
 
 for prGCD and 15.2 
 
±
 
 4.8 
 
µ
 
M
 
 for Cerezyme
 
®
 
).
These kinetic studies show that the activity of prGCD is similar
to that of the CHO-expressed enzyme.
 
Uptake and activity of prGCD by macrophages
 
The targeting and uptake of GCD by macrophages is medi-
ated by the Man/GlcNAc receptor, and can be determined
using murine thioglycolate-elicited peritoneal macrophages
(Stahl and Gordon, 1982). Our results demonstrated that
prGCD, expressed and purified from transformed carrot cells,
was taken up and targeted macrophage cells specifically
through Man/GlcNAc receptors without any need for re-
modelling 
 
in vitro
 
. Furthermore, the uptake and cellular
activity of prGCD was higher than that of Cerezyme
 
®
 
 at higher
concentrations (Figure 6a). Similar results were obtained using
cells isolated from patients with Gaucher’s disease (data
not shown). The addition of mannan inhibits the specific
uptake and internalization of both prGCD (Figure 6b) and
Cerezyme
 
®
 
  (Figure  6c), confirming that prGCD uptake is
mediated via Man receptors.
Figure 3 Glycan structures of recombinant 
glucocerebrosidase (GCD). (a) Major glycan 
structure analysis of recombinant plant-derived 
GCD (prGCD). In order to determine the glycan 
structure and ratios, sequential digestion with 
various exoglycosidases was performed. 
The glycans were fluorescently labelled, and 
sequencing of the glycan pool was achieved by 
high-performance liquid chromatography 
(HPLC) analysis. The retention times of 
individual glycans were compared with those 
of a standard partial hydrolysis of dextran giving 
a ladder of glucose units (GU). (b) Major glycan 
structure of GCD expressed in Chinese hamster 
ovary (CHO) cells before and after enzymatic 
deglycosylation. 
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X-Ray structure
The crystal structure of prGCD was determined by X-ray
crystallography. prGCD crystallized in a P21 space group with
two molecules in the asymmetric unit (Table S1, see ‘Supple-
mentary material’). It comprises three domains (Figure 7a).
Domain I (residues 1–27 and 384–414) consists of a three-
stranded anti-parallel β-sheet flanked by a perpendicular
amino-terminal strand. Domain II (residues 30–75 and
431–497) consists of two β-sheets. Domain III (residues 76–
381 and 416–430) is a (β/α)8 TIM barrel. Structural com-
parison of prGCD with both Cerezyme
® and Cerezyme
®
covalently modified by an irreversible inhibitor, conduritol-
B-epoxide (Dvir et al., 2003; Premkumar et al., 2005) [Protein
Data Bank (PDB) ID codes 1OGS and 1Y7V, respectively],
revealed highly significant structural identity. A least-squares
Cα superposition of the crystal structures of prGCD with
Cerezyme
® and with the Cerezyme
®–conduritol-B-epoxide
conjugate yielded overall root-mean-square distance (RMSD)
values of 0.64 and 0.60 Å, respectively. Furthermore, there
was strict conservation of the active site residues, E235 and
E340, and of neighbouring residues (Figure 7b).
Figure 4 Batch-to-batch reproducibility of the glycan profile of 
recombinant plant-derived glucocerebrosidase (prGCD). The glycoforms 
of prGCD (N-glycans) present in three independent batches were 
analysed by high-performance anion exchange chromatography with 
pulsed amperometric detection (HPAEC-PAD), following digestion with 
trypsin and peptide N-glycosidase A (PNGase A).
Figure 5 Kinetic analysis of glucocerebrosidase (GCD). Recombinant 
plant-derived GCD (prGCD) and Cerezyme
® (0.2 µg) were assayed 
using N-[6-[(7-nitrobenzo-2-oxa-1,3-diazol-4-yl)amino]hexanoyl]-
glucosylsphingosine (C6-NBD-GlcCer) (5 min, 37 °C) in 
2-(N-morpholino)ethanesulphonic acid (MES) buffer (50 mM, pH 5.5). 
The reaction was stopped by the addition of chloroform–methanol, prior 
to the extraction and analysis of fluorescent lipids. Michaelis–Menten 
kinetics were analysed using GraphPad Prism software. The data are the 
means of two independent experiments.
Figure 6 Uptake of recombinant plant-derived glucocerebrosidase 
(prGCD) by peritoneal macrophages. (a) Mouse macrophages were 
incubated with prGCD or Cerezyme
® at increasing concentrations, 
and GCD uptake and activity were measured in vitro with p-nitrophenyl-
β-D-glucopyranoside, and presented as the absorbance at 405 nm 
(OD, optical density). The effect of mannan on the specific uptake of 
prGCD (b) and Cerezyme
® (c) was tested, confirming that prGCD uptake 
is mediated via mannose receptors. Data are the means ± standard 
deviation of three independent experiments.584 Yoseph Shaaltiel et al.
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Toxicity study in mice
A single-dose toxicity study with prGCD was performed at
Harlan Biotech (Rehovot, Israel), in which vehicle solution
alone, or doses of prGCD in multiples of one, five or 10 times
the standard clinical dose (60 units/kg), were given to ICR
(CD-1
®) mice. The animals (six per group, three males and
three females) received the drug intravenously in a volume
of 10 mL/kg. As shown in Table 1, there were no obvious
treatment-related adverse reactions, no gross pathological
findings and no mortality incidences observed, even at the
highest dose administered. Furthermore, blood samples
taken from animals in the high-dose group, which had been
administered 10-fold the clinical dose, were tested for hae-
matology and clinical chemistry. All haematology and clinical
chemistry values were within normal ranges. In addition,
the animals treated with the high dose were subjected to
histopathological examination of the liver, spleen and kidney;
there were no macro- or micro-histopathological findings.
Discussion
This study demonstrates that carrot cells can produce active
human GCD, which has the potential to be used for ERT of
Gaucher’s disease. Earlier studies demonstrated the import-
ance of GCD glycosylation with terminal Man residues for
both its optimal activity and correct targeting to macro-
phages. Thus, GCD expressed in Escherichia coli is inactive,
and deglycosylation of GCD extracted from human placenta
results in a loss of enzymatic activity (Furbish et al., 1981;
Grace and Grabowski, 1990). GCD, after its production in
CHO cells, is enzymatically remodelled in vitro to expose the
terminal Man residues required for uptake by macrophages
(Friedman et al., 1999). The fact that prGCD produced in carrot
cells naturally possesses terminal Man residues represents an
important advantage of plant cells over mammalian cells for
the production of recombinant GCD for ERT. Plant cell cultures
have additional advantages over mammalian cells because
they do not require the presence of mammalian-derived
components in the manufacturing process, making the
purified biopharmaceutical products potentially safer and less
expensive (Sijmons et al., 1990; Hellwig et al., 2004).
Cerezyme
®  is currently the only recombinant GCD
approved for ERT for Gaucher’s disease, but its very high cost
places a heavy economic burden on healthcare systems
worldwide (Futerman et al., 2004). In contrast, prGCD does
not require costly enzymatic deglycosylation and provides
high batch-to-batch reproducibility of its glycan structures.
In addition, kinetic studies show that the activity of prGCD
is comparable with that of the CHO-expressed enzyme,
Cerezyme
®. This suggests that large-scale production of
prGCD may be more cost-effective than that of Cerezyme
®.
There are conflicting reports regarding the immunogenicity
of plant-derived biopharmaceutical glycoproteins (Cabanes-
Macheteau et al., 1999; Chargelegue et al., 2000; van Ree
et al., 2000). Bardor et al. (2003) have shown that 50% of
non-allergic blood donors have specific antibodies for core
xylose in their sera, and that 25% have specific antibodies to
core α-(1,3)-fucose. It remains to be determined whether
such antibodies may limit the use of plant-derived biophar-
maceutical glycoproteins. However, the current regulatory
viewpoint, based on data accumulated in a number of clinical
trials involving plant-expressed proteins, is quite promising
in this regard (Hellwig et al., 2004). Preclinical data from a
single-dose toxicity study with prGCD in mice, in multiples of
one, five and 10 times the clinical dose (60 units/kg), demon-
strated that there were no obvious treatment-related adverse
reactions or clinical findings, indicating the potential safety of
plant cell-expressed GCD. Currently, prGCD is undergoing
human clinical trials and additional preclinical studies.
Table 1 Toxicity study in mice. Six ICR (CD-1
®) mice per group (three males and three females) were intravenously administered one, five or 
10 times the human clinical dose of 60 units/kg. Control animals were administered a solvent control. Animals were monitored for 14 days 
following treatment. Clinical safety and pathological examinations were performed
Dose group Clinical observations Macroscopic examination
1 × clinical dose (1.8 mg/kg) No obvious treatment-related adverse reactions. 
Normal body weight gains. No deaths
No gross pathological findings
5 × clinical dose (9 mg/kg) No obvious treatment-related adverse reactions. 
Normal body weight gains. No deaths
No gross pathological findings
10 × clinical dose (18 mg/kg) No obvious treatment-related adverse reactions. 
Normal body weight gains. No deaths
No gross pathological findings
Solvent control No obvious treatment-related adverse reactions. 
Normal body weight gains. No deaths
No gross pathological findingsGlucocerebrosidase from plant cells for treating Gaucher’s disease 585
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Figure 7 Three-dimensional structure of recombinant plant-derived glucocerebrosidase (prGCD). (a) Domain I is in pink, domain II in green and domain 
III in cyan. The active site residues E235 and E340 are shown. Glycosylation detected at N19 is also shown. (b) Comparison of the catalytic residues of 
prGCD (blue), Cerezyme
® (pink) and a Cerezyme
®–conduritol-B-epoxide conjugate (yellow).586 Yoseph Shaaltiel et al.
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Based on an examination of the entries in the PDB, the
structure reported here for prGCD is the first example of the
determination of a three-dimensional crystal structure of a
human protein produced in a plant recombinant expression
system. It is interesting to note the similarity of its three-
dimensional structure to that of the same enzyme expressed
in CHO cells (Dvir et al., 2003; Premkumar et al., 2005; Liou
et al., 2006), showing, for the first time, the extremely high
similarity of plant and mammalian cell machineries control-
ling the folding and assembly of proteins within their
endomembrane systems.
In summary, this study describes the expression of recom-
binant GCD in transgenic plant cells. prGCD is highly homo-
logous to Cerezyme
®, both structurally and biologically. The
availability of a high-resolution structure for prGCD will allow
future modifications of its structure, perhaps permitting,
thereby, improved therapeutic activity. The plant cell system
developed here has the potential to be highly advantageous
for the production of additional therapeutic recombinant
glycoproteins that are not suitable for production in bacterial
hosts, and are currently being expressed in costly mammalian
expression systems.
Experimental procedures
Construction of the expression plasmid
The cDNA encoding GCD (ATTC clone #65696) was subcloned into
a  plasmid containing the signal peptide from the Arabidopsis
thaliana basic endochitinase gene (Samac et al., 1990) and the
vacuolar targeting signal from tobacco chitinase A (Neuhaus et al.,
1991). At the 5′ end of the open reading frame, the plasmid con-
tained the 35S promoter from cauliflower mosaic virus (Odell et al.,
1985), followed by the tobacco mosaic virus (TMV) omega trans-
lational enhancer element (Gallie and Kado, 1989). At the 3′ end, the
octopine synthase terminator sequence from Agrobacterium tume-
faciens (Dhaese et al., 1983) was inserted. The cassette was removed
from the intermediate vector and ligated into the binary vector
pGREENII (obtained from Dr P. Mullineaux, John Innes Centre, Nor-
wich Research Park, Colney, UK) (Hellens et al., 2000). Kanamycin
resistance was conferred by the neomycin phosphotransferase type
II (NPTII) gene driven by the nos promoter.
Transformation and isolation of carrot cells
Carrot calli and cell suspension cultures were produced as described
previously (Torres, 1983), and carrot cells were transformed using
Agrobacterium (Wurtele and Bulka, 1989) with some modifications.
Briefly, Agrobacterium was transformed with the pGREENII-nos-
kan-GCDvac vector by electroporation (den Dulk-Ras and Hooykaas,
1995), and selected using 30 mg/mL paromomycin. Carrot cells were
transformed with Agrobacterium, and selected using 60 mg/mL of
paromomycin in liquid medium.
Gel electrophoresis and Coomassie staining
Sodium dodecylsulphate-polyacrylamide gel electrophoresis
(SDS-PAGE) was performed under standard conditions, using a
Criterion™ cell vertical electrophoresis apparatus (Bio-Rad, Hercules,
CA, USA) with premixed tris(hydroxymethyl)aminomethane (Tris)–
glycine–SDS electrophoresis running buffer (Bio-Rad); 15% acryla-
mide gels were prepared using premixed solutions of 40% acryla-
mide/Bis, resolving gel buffer, stacking gel buffer (Bio-Rad) and 10%
aqueous SDS. Commercial molecular weight markers were used to
assess the molecular weight of prGCD. Sample buffer (Laemmli,
1970) was used to treat each sample, and the mixture was boiled for
3 min before loading on to the gel. The gels were stained with Bio-
Safe™ Coomassie Stain (Bio-Rad), as directed by the manufacturer.
Antibody production and Western blotting
Cerezyme
® (75 µg) was suspended in 3 mL complete Freund’s
adjuvant and injected into New Zealand rabbits. A booster injection
was given after 2 weeks and the rabbits were bled 10 days later and
at 1-week intervals until the antibody titre began to drop. Serum was
stored at –20 °C. For Western blotting, protein extracts were separated
by SDS-PAGE (Laemmli, 1970) as described above, transferred to
a nitrocellulose membrane (Amersham Life Science, Amersham,
Buckinghamshire, UK), and GCD was detected using anti-GCD anti-
body (diluted 1 : 6500) and a peroxidase-conjugated goat anti-rabbit
horseradish peroxidase (HRP) secondary antibody (diluted 1 : 15 000)
(Sigma, Rehovot, Israel).
prGCD purification
Cells were thawed overnight at 4 °C, and prGCD was extracted by
homogenization in 20 mM sodium phosphate, pH 7.2, containing
0.1 mM  phenylmethanesulphonyl fluoride, 20  mM  ascorbic acid,
0.1 mM DL-dithiothreitol, 1% Triton X-100 and 20 mM ethylenedi-
aminetetraacetic acid (EDTA). Following centrifugation (17 000 g,
20 min), the supernatant was applied to a strong cation exchange
resin (Macro-Prep high-S support, Bio-Rad) that had been pre-
equilibrated with 25 mM sodium citrate, pH 5.5. The prGCD fraction
was subsequently applied to a hydrophobic interaction resin (TSK gel,
Toyopearl Phenyl-650C, Tosoh Corp, Tokyo, Japan), pooled and
further purified using a strong cation exchange column (Macro-Prep
high-S support, Bio-Rad). The protein concentration was determined
using either the Bradford method (Bradford, 1976), or from the
absorbance (optical density, OD) at 280 nm (1 mg/mL = 1.53OD280).
Sequence determination
Liquid chromatography-mass spectrometry/mass-spectrometry
(LC-MS/MS) and Edman degradation were performed at the Smoler
Proteomic Center, Technion, Haifa, Israel. Purified prGCD was separ-
ated by SDS-PAGE, followed by tryptic digestion, removal of the
sugars using peptide N-glycosidase A (PNGase A) and LC-MS/MS.
The trypsinized peptides were separated by reverse-phase chroma-
tography on 0.1 × 300-mm fused silica capillaries (J&W, 100 µm inside
diameter, Wilmington, DE, USA), and eluted using a linear gradient
of 5%–95% acetonitrile containing 0.1% formic acid. Elution
fractions were electrosprayed on to an ion-trap mass spectrometerGlucocerebrosidase from plant cells for treating Gaucher’s disease 587
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(DecaXP, Finnigan, San Jose, CA, USA). MS was performed in the
positive ion mode using a repetitively full MS scan, followed by
collision-induced dissociation (CID) of the most dominant ion selected
from the first MS scan. The MS data were compared with simulated
proteolysis and collision-induced fragmentation of the proteins, us-
ing the NR-NCBI database and Sequest software (J. Eng and J. Yates,
University of Washington, Seattle, WA, USA and Finnigan) with unified
Score 2400 and Pep-Miner software (IBM Haifa Research Laboratory,
Haifa, Israel).
Glycosylation analysis
Glycosylation patterns were analysed by the Glycobiology Center,
National Institute for Biotechnology, Ben Gurion University, Beer
Sheba, Israel to determine the glycan structure and relative amounts
using sequential digestion with various exoglycosidases. The prGCD
samples were run on SDS-PAGE, and a 61-kDa band was cut out and
incubated with either PNGase A or trypsin followed by PNGase A to
release the N-linked glycans. The glycans were fluorescently labelled
with anthranilamide (2AB) and run on normal phase HPLC.
Sequencing of the labelled glycan pool was achieved by sequential
digestion with various exoglycosidases, followed by HPLC analysis.
The retention times of the individual glycans were compared with
those of a standard partial hydrolysate of dextran giving a ladder
of glucose units (GU). Unlabelled glycans were further purified and
analysed by DE-MALDI-TOF-MS.
The exoglycosidases used were as follows: bovine kidney α-fucosidase
(digests α1–6 and α1–3 core fucose; Prozyme, San Leandro, CA,
USA); jack bean mannosidase (removes α1–2, 6 > 3 Man; Prozyme);
Xanthomonas β-1,2-xylosidase (removes β1–2 xylose only after
removal of α-linked Man; Calbiochem, San Diego, CA, USA); bovine
testes β-galactosidase (hydrolyses non-reducing terminal galactose
β1–3 and β1–4 linkages; Prozyme); Streptococcus pneumoniae hexo-
saminidase [digests β1–2,3,4,6 N-acetyl-D-galactosamine (GalNAc)
and GlcNAc; Prozyme].
Glycosylation was further analysed by M-Scan (Wokingham, Berk-
shire, UK) using gas chromatography-mass spectrometry (GC-MS), fast
atom bombardment-mass spectrometry (FAB-MS) and DE-MALDI-
TOF-MS. For oligosaccharide determination, the N-glycan population
was analysed by FAB-MS and DE-MALDI-TOF-MS, following diges-
tion of samples with trypsin and PNGase A, and permethylation of
the glycans. O-Glycans were analysed following reductive elimination
of the tryptic and PNGase A-treated glycopeptides, desalting and
permethylation. The similarity of the N-glycans in different batches
of prGCD was analysed by high-performance anion exchange
chromatography with pulsed amperometric detection (HPAEC-PAD,
a Dionex method), following digestion with trypsin and PNGase A,
to obtain chromatographic profiles for the oligosaccharides released
from glycoproteins for the purpose of demonstrating consistency
from batch to batch of prGCD. This procedure permits chromato-
graphic comparison of oligosaccharide patterns in a qualitative and
quantitative manner.
In vitro enzymatic assay
prGCD was routinely assayed using p-nitrophenyl-β-D-glucopyranoside.
The assay buffer contained 4 mM β-mercaptoethanol, 1.3 mM EDTA,
0.15% Triton X-100, 0.125% sodium taurocholate and 60  mM
phosphate–citrate buffer, pH 6.0. After 60 min at 37 °C, the reaction
was terminated using 5 M NaOH, and the reaction product (p-
nitrophenol) was determined by its absorbance at 405 nm (Friedman
et al., 1999). For kinetic studies, GCD activity was assayed as de-
scribed by Meivar-Levy et al. (1994), with some modifications, using
a fluorescent short-acyl-chain analogue of GlcCer, N-[6-[(7-nitrobenzo-
2-oxa-1,3-diazol-4-yl)amino]hexanoyl]-D-erythro-glucosylsphingo-
sine (C6-NBD-D-erythro-GlcCer). C6-NBD-GlcCer was synthesized by
N-acylation of glucosylsphingosine using succinimidyl-6-(7-nitrobenzo-
2-oxa-1,3-diazol-4-yl)aminohexanoate, as described by Schwarzmann
and Sandhoff (1987). The assay was performed using 0.2 µg of
either Cerezyme
® or prGCD in a final volume of 200 µL 2-(N-
morpholino)ethanesulphonic acid (MES) buffer (50  mM, pH  5.5).
Concentrations of C6-NBD-GlcCer ranged from 0.25 to 100 µM.
Reactions were allowed to proceed for 5 min at 37 °C, and were
stopped by the addition of 1.5 mL of chloroform–methanol (1 : 2, v/v)
prior to extraction and analysis of the fluorescent lipids.
prGCD uptake by macrophages
Thioglycolate-elicited peritoneal macrophages were obtained from
mice (Stahl and Gordon, 1982). Briefly, cells were collected by
centrifugation (1200 g, 10 min), resuspended in Dulbecco’s modified
Eagle’s medium (DMEM) (Beit Haemek, Israel) containing 10% fetal
calf serum, plated at (1–2) × 10
5 cells/well in 96-well plates, and
incubated at 37 °C for 90 min prior to the removal of non-adherent
cells. Adherent cells were further incubated for 90 min at 37 °C in
culture medium containing prGCD or Cerezyme
®, with or without
mannan (Sigma). Medium was subsequently removed, the cells were
washed three times with phosphate-buffered saline (PBS), followed
by lysis using 10 mM Tris, pH 7.3 containing 0.5% Nonidet P40
(NP-40), 1 mM MgCl2 and a protease inhibitor cocktail (Sigma). The
activity of prGCD taken up by the cells was determined by enzymatic
activity assay.
X-Ray crystallography
Single crystals of prGCD were obtained by the microbatch method
under oil, using an Oryx6 robot (Douglas Instruments Ltd., East
Garston, Berkshire, UK). Crystals were grown at 20 °C from a pre-
cipitating solution of 25% w/v polyethylene glycol 3350 in 10 mM
hexamine cobalt(III) chloride/0.2 M (NH4)2SO4/100 mM bis-Tris, pH 6.5.
Crystals were cryoprotected with 25% glycerol. A complete data set
was collected from a single crystal on beamline ID14-4 at the European
Synchrotron Radiation Facility (Grenoble, France) at 100 K. Diffraction
data were integrated, scaled and reduced using the HKL program
package (Otwinowski and Minor, 1997). The prGCD structure was
solved by molecular replacement using the program PHASER (Storoni
et al., 2004), taking the 2 Å refined structure of human GCD (PDB ID
code 1OGS) as the starting model (Dvir et al., 2003; Premkumar
et al., 2005). Atomic refinement was carried out with the program
CNS (Brunger et al., 1998). After one round of simulated annealing,
Fo-Fc and 3Fo-2Fc maps were used to fit the prGCD molecule,
three sugar moieties, bis-Tris and nine sulphate molecules. Two-fold
non-crystallographic restraints were applied in all the refinement
cycles. Map display and model rebuilding were performed using the
program O (Jones and Kjeldgaard, 1997), and the quality of the model
was checked using PROCHECK (Laskowski et al., 1993). Refinement and588 Yoseph Shaaltiel et al.
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model statistics are presented in Table S2 (see ‘Supplementary mate-
rial’) Coordinates and structure factors have been deposited in PDB.
Toxicity study in mice
A single-dose toxicity study with prGCD was performed at Harlan
Biotech (Rehovot, Israel) by intravenous injection in ICR (CD-1
®) mice
to provide information for the basis for the selection of appropriate
dose levels in further repeated dosing trials. In view of the lack of
information on the potential acute intravenous toxicity of prGCD in
preclinical studies, an initial target dose of 1.8 mg/kg (60 units/kg –
the clinical dose level), followed by additional dose levels of 9
and 18 mg/kg, was selected (one, five or 10 times the human clinical
dose). prGCD-treated groups comprised six ICR (CD-1
®) mice (three
males and three females) aged 5 weeks at study initiation, and a
single group of equal size treated with solvent only (25 mM citrate
buffer, 150 mM NaCl, 0.01% Tween 80 and 5% ethanol) served
as the control group. In all instances, prGCD-treated animals and
controls were administered at a uniform volume dosage of 10 mL/kg.
Clinical signs, behaviour and body weight gain/loss were monitored
for 14 days following dose administration. Gross pathological exam-
ination was performed for all animals. Animals receiving the highest
dose tested were subjected to haematology and clinical chemistry
evaluation, and to histopathological examination of the liver, spleen
and kidney.
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